Monitoring the Patient Following Radio-Cephalic Arteriovenous Fistula Creation: Current Perspectives.

Vasc Health Risk Manag · 2021 · PMC8040072 · PMID 33854321

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In April 2019, Proteon Therapeutics (Waltham, MA) reported that the study did not reach statistical significance in primary or secondary patency. 66 Vascugel (Pervasis Therapeutics, Inc., Cambridge, MA) is a product that uses differentiated adult allogeneic endothelial cells embedded in a patented polymer matrix system.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.